William Blair compared Tezspire’s results with Sanofi SA (NASDAQ:SNY) and Regeneron Pharmaceutical Inc‘s (NASDAQ:REGN) Dupixent, demonstrating a 30% and 34% decrease in annualized moderate or ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Read Next: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs. Sanofi/Regeneron’s Blockbuster Dupixent – Analyst Gives His Pick. Price Action: SNY shares are up 5.40% at $49.13 at the last check ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

After several months, inflammatory disease medication Dupixent has finally reclaimed its spot atop the rankings for over-the-counter (OTC) and Rx brand marketing on TV. The Regeneron and Sanofi brand, ...

AEs more commonly observed with Dupixent compared to placebo in at least 3 patients included peripheral edema (n=8 vs. n=5), arthralgia (n=5 vs. n=3), back pain (n=4 vs. n=2), blurred vision (n=4 vs.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

AEs more commonly observed with Dupixent compared to placebo in at least 3 patients included peripheral edema (n=8 vs. n=5), arthralgia (n=5 vs. n=3), back pain (n=4 vs. n=2), blurred vision (n=4 vs.